Sponsor Pipeline

Imbioray (Hangzhou) Biomedicine Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
3
Recruiting
4
Disease Areas
Active Trials by Phase
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07087158 A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell… Renal Cell Carcinoma (RCC) Recruiting
Phase 1
NCT06234904 Study of IBR733 Cell Injection in Acute Myeloid Leukemia Acute Myeloid Leukemia Recruiting
NCT07073833 The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory… Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting
Disease Areas
Leukemia (1) Acute Myeloid Leukemia (AML) (1) Non-Hodgkin Lymphoma (1) Kidney Cancer (1)
Get alerts when Imbioray (Hangzhou) Biomedicine Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free